- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07938606
MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)
A Phase Ib/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Pediatric Patients Aged 6 to 12 Years With Moderate to Severe Atopic Dermatitis
A Phase Ib/II Study of MG-K10 in Pediatric Patients (6-12 Years) with Moderate to Severe Atopic Dermatitis
Primary Objective:
To evaluate the safety of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the pharmacokinetic (PK) characteristics, preliminary efficacy, pharmacodynamic (PD) characteristics, and immunogenicity of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe AD.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Ma
- Telefoonnummer: 13601305676
- E-mail: bch_maleen2021@126.com
Studie Locaties
-
-
-
Shanghai, China
- Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
-
Contact:
- Chao Deng
- Telefoonnummer: 15712950928
- E-mail: chao.deng@mabgeek.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aged ≥6 years and <12 years (calculated based on the date of ICF signature), regardless of gender, with a baseline body weight ≥15 kg and <60 kg.
- Diagnosed with atopic dermatitis (AD) according to the American Academy of Dermatology (AAD) consensus criteria (2014), with a history of AD or eczema diagnosed for ≥6 months prior to screening (with disease onset defined as the date of first symptom appearance).
- Inadequate response to topical medications within 12 months prior to screening, or medically unsuitable for topical medication therapy.
- Participants and/or their parents or legal guardians voluntarily provide written informed consent. For participants aged ≥6 years and <8 years, signing an informed consent form is not required, but an assent form must be completed. Participants must be able to communicate effectively with the investigator and comply with protocol-required follow-up visits.
Exclusion Criteria:
- Unable to undergo subcutaneous injection
- Have other active skin diseases that may affect AD evaluation (such as psoriasis or lupus erythematosus);
- Have diseases that may require systemic glucocorticoid or immunosuppressant treatment;
- Patients with ocular diseases deemed unsuitable for enrollment by the investigator;
- Received allergen-specific immunotherapy within 6 months before dosing; Stopped all topical medications less than 2 weeks before dosing, including topical glucocorticoids, topical calcineurin inhibitors, antibiotic compound creams, topical TCM therapy;
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: A:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
Experimenteel: B:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
Experimenteel: C:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
Experimenteel: D:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence and severity of adverse events
Tijdsspanne: Up to Week 24
|
Incidence and severity of AEs, plus abnormality rates/severity of vital signs, physical examination, clinical laboratory tests, and 12-lead ECG. |
Up to Week 24
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent of Participants with Investigator's Global Assessment (IGA) 0/1 and ≥2-Point Improvement
Tijdsspanne: Each assessment visit through Week 16
|
Proportion achieving IGA score 0 or 1 AND ≥2-point reduction vs. baseline |
Each assessment visit through Week 16
|
|
Percent of Participants with ≥2-Point IGA Improvement
Tijdsspanne: Through Week 16
|
Proportion with IGA reduction ≥2 points vs. baseline |
Through Week 16
|
|
Percent of Participants Achieving EASI-50, EASI-75, or EASI-90
Tijdsspanne: Through Week 16
|
Proportion with ≥50%/75%/90% EASI reduction vs. baseline |
Through Week 16
|
|
Change in Lesion Body Surface Area (BSA)
Tijdsspanne: Through Week 16
|
Change in lesion body surface area |
Through Week 16
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Genetische ziekten, aangeboren
- Ziekten van het immuunsysteem
- Overgevoeligheid, Onmiddellijk
- Overgevoeligheid
- Huidziektes
- Huidziekten, genetisch
- Huidziekten, Eczeem
- Dermatitis
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Huid- en bindweefselaandoeningen
- Dermatitis, atopisch
- Dermatologische middelen
- Farmacologische acties
- Chemische acties en gebruik
- Therapeutisch gebruik
- Verzachtende middelen
Andere studie-ID-nummers
- MG-K10-AD-007
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .